Baganz L, et al. - Authors sought to investigate the long-term efficacy and retention rates of Tocilizumab (TCZ) in subjects with different numbers of prior bDMARD failures. According to the results, in patients with no, one or two prior bDMARD failures, TCZ was similarly effective. Low disease activity (LDA) was noted to be achieved by a majority of the subjects after 6 months, which was maintained over a period of 3 years. Even in the high-risk group of subjects having more than 2 prior bDMARD failures, TCZ proved efficacious.